Skip to content

Dyne Therapeutics on deck for IPO

August 26, 2020

Dyne Therapeutics (DYN) has filed a preliminary prospectus for a $100M IPO.

The Waltham, MA-based biotech develops therapies for genetically driven disorders using its FORCE platform to overcome the limitations of muscle tissue delivery and advance oligonucleotide therapeutics for muscle diseases. Top pipeline programs are myotonic dystrophy, Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy.

2020 Financials (6 mo.): Operating Expenses: $16.5M (+251%); Net Loss: ($16.9M) (-369%); Cash Burn: ($14.6M) (-204%).

Potential competitors: Sarepta Therapeutics (NASDAQ:SRPT), NS Pharma (OTC:NPNKF), Pfizer (NYSE:PFE), Capricor Therapeutics (NASDAQ:CAPR), Catabasis Pharmaceuticals (NASDAQ:CATB), Solid Biosciences (NASDAQ:SLDB), PTC Therapeutics (NASDAQ:PTCT), Avidity Biosciences (NASDAQ:RNA), Vertex Pharmaceuticals (NASDAQ:VRTX), Fulcrum Therapeutics (NASDAQ:FULC)

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: